



fresh
insights

March 2019 Edition: DVT Awareness Month

Conference Updates: ACE Breakfast Workshop, VTE Session Highlight * Explore ACE Website * AC Forum March Webinar * Literature Updates: VTE Highlights * AC Forum Order Sets - PAD and VTE Prophylaxis * Joint Commission Webinar

15 National Conference on Anticoagulant Therapy April 11 - 13, 2019 | The Diplomat Resort | Fort Lauderdale, FL



Session Highlight: Controversies and Challenges in VTE

Join us Friday during the conference for a special focus on VTE, including these informative sessions:

- VTE Treatment Debate - Drug, Duration and Dose
- Imaging Dilemmas in VTE
- Managing VTE in Cancer Patients


Anticoagulation Centers of Excellence (ACE) Workshop

Join us for breakfast Friday morning for a discussion about the benefits and challenges of becoming an Anticoagulation Center of Excellence (ACE). Meet with participants and the leadership committee and hear from practices that have embarked on this rewarding program. There is no cost to attend - sign up today by emailing jen@acforum.org.

Join Us

Join us at our 15 National Conference on Anticoagulant Therapy, April 11-13, 2019 at the Diplomat Resort in Ft. Lauderdale, FL. Read more about our [program](#) and [faculty](#) and reserve your spot today!

Register



What's the AC Forum's Centers of Excellence all about?

Explore ACE and qualify to win Apple AirPods! Visit the [Anticoagulation Forum Centers of Excellence](#) to find answers to questions, while learning valuable information about the features on our site. If you correctly answer at least 10 questions, you will be entered into a random drawing for a pair of Apple AirPods! The drawing will be held during our national conference, April 11-13. You do not need to be present to win.

Explore



Anticoagulation
FORUM

Webinar ►
Lunch & Learn

Isolated Distal DVT: Selecting the Best Management Strategies

Tuesday | March 19, 2019 | 12:00 PM ET

Guest Speaker:

Natalie Evans, MD, Cleveland Clinic; National AHA Spokesperson

AC Forum Moderators:

Sara Vazquez, PharmD; Diane Wirth, ANP

March is DVT Awareness Month - Join the AC Forum and American Heart Association in this special joint webinar.

Dr. Natalie Evans, Medical Director of the Non-Invasive Vascular Laboratory and a vascular medicine specialist at the Cleveland Clinic will discuss the best management strategies for isolated distal DVT with a panel of multidisciplinary experts from the Anticoagulation Forum.

Register

Centers of Excellence Resource Center Literature Updates: Spotlight on DVT

A few weeks ago we introduced you to one of our newest features - the bi-weekly literature updates in the ACE Resource Center. Since its release it has become our most popularly accessed resource.

This month, to celebrate DVT awareness month we are highlighting some of the most recent articles on this topic:

- Deep vein thrombosis in upper extremities: Clinical characteristics, management strategies and long-term outcomes from the COMMAND VTE Registry
- Hospitalization as a trigger for venous thromboembolism - Results from a population-based case-crossover study
- Long-Term Management of Venous Thromboembolism: Lessons from EINSTEIN CHOICE and Other Extension Trials

[Literature Updates](#)

New Order Sets for PAD and VTE Prophylaxis

The AC Forum has published two new order sets to help guide your patient care.

[Order Set for Safe initiation of DOAC for patients with CAD/PAD already on guideline directed therapy](#)

This order set may be used for patients diagnosed with stable coronary artery disease

(CAD) and/or peripheral artery disease (PAD) who are already being treated with guideline directed antiplatelet therapy and require prescription of adjunct direct oral anticoagulant therapy in an inpatient or outpatient setting.

[Order Set for VTE prophylaxis for the medically ill patient](#)

This order set is intended to facilitate standardized venous thromboembolism (VTE) prophylaxis risk stratification of hospitalized medically ill patients for:

- Hospital-acquired VTE
- Prophylaxis-associated bleeding on anticoagulation administration
- Prescription of risk-appropriate VTE prophylaxis



Preparing for new Joint Commission EPs effective July 1: Best Practices in Anticoagulant Therapy Webinar

Tuesday, Apr 2, 2019 11:00 AM CDT

Speakers:

Scott Kaatz, DO, AC Forum Board President
William Dager, PharmD, AC Forum Board Member

Webinar Series Description and Objectives:

Anticoagulation therapy remains a commonly prescribed and used class of drugs, but it is also a leading cause of avoidable severe medication related adverse events. This webinar series will address each of the proposed safety measures targeted for implementation and provide insights on implementing systems to health care settings to successfully achieve established targets.

This session seeks to:

- Share best practices in anticoagulant therapy
- Assist health care organizations to better understand and implement the new EPs
- Answer participant questions about the new Anticoagulant Therapy elements of performance during the live session

Experts from the Anticoagulation Forum, Scott Kaatz, DO, MSc, FACP, SFHM, Wayne State University and Henry Ford Hospital and William E. Dager, PharmD, BCPS (AQ-Cardiology), UC Davis Medical Center will present on the April 2 webinar session, the first of the two-part series. See the registration page for additional biographical information about our presenters. There will also be a live Q&A session.

Effective July 1, 2019, eight new Anticoagulant Therapy elements of performance (EPs) within the National Patient Safety Goals (NPSG.03.05.01) go into effect for all Joint Commission-accredited hospitals, critical access hospitals, nursing care centers, and medical centers (accredited under the ambulatory health care program). A rise in adverse drug events associated with direct oral anticoagulants (DOACs) led The Joint Commission to update this NPSG to address DOACs and help to reverse that trend. The Joint Commission has scheduled a two-part webinar series (April and May) to show best practices and to assist customers in answering questions about implementation ahead of the July 1 effective date.

For additional information about these new Anticoagulant Therapy EPs, see the [NPSG Anticoagulant Therapy R3 Report | Requirement, Rationale, Reference](#) issued in The Joint Commission December 2018 R3 Report.

[REGISTER](#)

Thank you to our newsletter sponsors

